Evaluation of ocrelizumab in older progressive multiple sclerosis patients
S Epstein, KT Fong, PL De Jager, L Levine… - Multiple Sclerosis and …, 2021 - Elsevier
Background Seminal trials evaluating anti-CD20 therapy in progressive MS primarily found
benefit in younger, less-disabled patients with more inflammatory disease activity. The risks …
benefit in younger, less-disabled patients with more inflammatory disease activity. The risks …
Real‐world evaluation of ocrelizumab in multiple sclerosis: A systematic review
X Montalban, PM Matthews, A Simpson… - Annals of clinical …, 2023 - Wiley Online Library
Across its clinical development program, ocrelizumab demonstrated efficacy in improving
clinical outcomes in multiple sclerosis, including annualized relapse rates and confirmed …
clinical outcomes in multiple sclerosis, including annualized relapse rates and confirmed …
Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population
E Fernandez‐Diaz, JA Perez‐Vicente… - Annals of Clinical …, 2021 - Wiley Online Library
Objective Pivotal trial have shown that patients with multiple sclerosis (MS) receiving
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …
Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing–similar clinical efficacy with decreased immunoglobulin M deficiency rates
T Rempe, A Elfasi, E Rodriguez, M Vasquez… - Multiple Sclerosis and …, 2023 - Elsevier
Background Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody used in
treatment of multiple sclerosis. The standard dosing (SD) regimen consists of OCR …
treatment of multiple sclerosis. The standard dosing (SD) regimen consists of OCR …
Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review
HS Ng, CL Rosenbult, H Tremlett - Expert Opinion on Drug Safety, 2020 - Taylor & Francis
Introduction We systematically reviewed adverse events (AEs) for ocrelizumab for multiple
sclerosis (MS). Areas covered We searched Medline, Embase, Web of Science, and …
sclerosis (MS). Areas covered We searched Medline, Embase, Web of Science, and …
Tolerability and safety of switching from rituximab to ocrelizumab: evaluating factors associated with infusion related reactions
Background Ocrelizumab and rituximab are frequently used treatments for multiple sclerosis
(MS). Data on switching from rituximab to ocrelizumab is limited. Objectives To assess the …
(MS). Data on switching from rituximab to ocrelizumab is limited. Objectives To assess the …
Real-world experience of ocrelizumab in multiple sclerosis in an Arab population
B Garcia-Cañibano, S Ouanes… - Journal of Drug …, 2021 - Taylor & Francis
Objective Pivotal clinical trials revealed good clinical efficiency of ocrelizumab while having
a good safety profile in the management of multiple sclerosis (MS). However, real-world data …
a good safety profile in the management of multiple sclerosis (MS). However, real-world data …
Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts …
P Dirks, V Zingler, J Leemhuis, H Berthold… - BMC neurology, 2020 - Springer
Background Multiple sclerosis (MS) is a chronic disease that requires lifelong treatment. A
highly effective drug not only for relapsing but also for progressive forms of MS with a …
highly effective drug not only for relapsing but also for progressive forms of MS with a …
Real world study of ocrelizumab in multiple sclerosis: Kuwait experience
R Alroughani, M AlMojel, J Al-Hashel… - Multiple Sclerosis and …, 2023 - Elsevier
Background Ocrelizumab is a humanized anti-CD20 antibody that has been approved for
the treatment of patients with multiple sclerosis (MS). Real-world data in the Middle East is …
the treatment of patients with multiple sclerosis (MS). Real-world data in the Middle East is …